Intangible Assets

XOMA does not appear to rely on durable patents, proprietary formulations, or regulated exclusivity that would create peer-leading pricing power, so its intangible asset moat is materially weaker than branded pharma peers and most specialty biotech platforms.

The company’s value is more tied to financial assets and transaction-driven economics than to a protected product franchise, which makes its competitive advantage less durable than peers with recurring IP-backed revenue streams.

No evidence in the provided metrics indicates sustained margin power from unique intangible assets, and the low TTM ROIC/ROCE versus typical biotech hurdle rates suggests limited monetization of any intangible edge relative to peers.

Switching Costs

XOMA does not show customer lock-in from mission-critical software, embedded workflows, or long-duration service contracts, so buyers and partners can more easily substitute alternatives than in peer businesses with high integration costs.

The company’s economics do not indicate strong retention-driven pricing power, and the negative cash conversion cycle reflects working-capital dynamics rather than customer dependence that would raise switching friction.

Compared with peers that sell approved therapies, platform tools, or regulated services, XOMA appears to have materially lower switching costs because counterparties are not structurally dependent on its offerings for core operations.

Network Effects

XOMA does not exhibit a visible network effect where more users, data, or counterparties directly increase product value for existing customers, unlike peer platforms that compound adoption through ecosystem feedback loops.

There is no evidence of a self-reinforcing user or partner base that would make the company harder to displace over 5–10 years, so any competitive advantage is not network-driven.

Relative to peers with data-rich or platform-based models, XOMA lacks the structural flywheel that typically supports durable retention and expanding pricing power.

Cost Advantage

XOMA’s TTM ROIC of about 1.9% and ROCE of about 2.1% suggest it is not converting capital into returns at a level that would indicate a durable cost advantage versus stronger peers.

The company’s asset turnover of 0.13 implies low operating efficiency, which weakens the case that it can sustainably underprice or outproduce competitors while preserving margins.

Compared with peers that benefit from scale manufacturing, proprietary distribution, or high fixed-cost absorption, XOMA does not show evidence of a structurally lower cost base.

Efficient Scale

XOMA does not appear to operate in a market where a small number of firms naturally support high barriers from efficient scale, because its business model does not show the kind of infrastructure concentration that limits entry.

The absence of strong recurring revenue or platform concentration reduces the likelihood that scale alone protects margins, unlike peers in niche tools, regulated services, or dominant distribution networks.

Relative to peers with entrenched scale advantages, XOMA’s economics do not indicate that market size or capacity constraints are creating durable protection from competition.

Overall Score

XOMA’s moat appears weak versus peers because the provided metrics and business profile do not show durable IP, meaningful switching costs, network effects, cost leadership, or efficient-scale protection, and the low ROIC/ROCE reinforces limited evidence of sustained pricing power or retention over a 5–10 year horizon.